Rctd-031

Groundbreaking technologies or products often lead to the creation of new markets, jobs, and economic opportunities. They can also disrupt existing industries, leading to a transformation in how businesses operate.

If the Phase 3 data confirm these trends, RCTD‑031 could become a that reshapes treatment algorithms for fibrotic diseases. rctd-031

| Date | Milestone | |------|-----------| | Q4 2026 | Completion of Phase 1/2 (full dataset) | | Q2 2027 | End‑of‑Phase 2 meeting with FDA (potential for accelerated approval pathway) | | H2 2027 | Initiation of pivotal Phase 3 trials (IPF & hATTR) | | 2028‑2029 | Regulatory submissions (US, EU, Japan) | Groundbreaking technologies or products often lead to the

RCTD-031 might also be associated with environmental science, specifically projects or products focused on sustainability, climate change mitigation, or pollution control. This could involve innovative solar panel technology, carbon capture methods, or sustainable materials. | Date | Milestone | |------|-----------| | Q4